000163952 001__ 163952
000163952 005__ 20240315115353.0
000163952 0247_ $$2pmc$$apmc:PMC9321158
000163952 0247_ $$2doi$$a10.1002/mds.29005
000163952 0247_ $$2pmid$$apmid:35445419
000163952 0247_ $$2ISSN$$a0885-3185
000163952 0247_ $$2ISSN$$a1531-8257
000163952 0247_ $$2altmetric$$aaltmetric:127044895
000163952 037__ $$aDZNE-2022-00626
000163952 041__ $$aEnglish
000163952 082__ $$a610
000163952 1001_ $$aWenning, Gregor K$$b0
000163952 245__ $$aThe Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.
000163952 260__ $$aNew York, NY$$bWiley$$c2022
000163952 3367_ $$2DRIVER$$aarticle
000163952 3367_ $$2DataCite$$aOutput Types/Journal article
000163952 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655991523_2096$$xReview Article
000163952 3367_ $$2BibTeX$$aARTICLE
000163952 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163952 3367_ $$00$$2EndNote$$aJournal Article
000163952 500__ $$a(CC BY)
000163952 520__ $$aThe second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to diagnose the disease at early stages.To develop novel Movement Disorder Society (MDS) criteria for MSA diagnosis using an evidence-based and consensus-based methodology.We identified shortcomings of the second consensus criteria for MSA diagnosis and conducted a systematic literature review to answer predefined questions on clinical presentation and diagnostic tools relevant for MSA diagnosis. The criteria were developed and later optimized using two Delphi rounds within the MSA Criteria Revision Task Force, a survey for MDS membership, and a virtual Consensus Conference.The criteria for neuropathologically established MSA remain unchanged. For a clinical MSA diagnosis a new category of clinically established MSA is introduced, aiming for maximum specificity with acceptable sensitivity. A category of clinically probable MSA is defined to enhance sensitivity while maintaining specificity. A research category of possible prodromal MSA is designed to capture patients in the earliest stages when symptoms and signs are present, but do not meet the threshold for clinically established or clinically probable MSA. Brain magnetic resonance imaging markers suggestive of MSA are required for the diagnosis of clinically established MSA. The number of research biomarkers that support all clinical diagnostic categories will likely grow.This set of MDS MSA diagnostic criteria aims at improving the diagnostic accuracy, particularly in early disease stages. It requires validation in a prospective clinical and a clinicopathological study. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000163952 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000163952 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163952 650_7 $$2Other$$adiagnosis
000163952 650_7 $$2Other$$adiagnostic criteria
000163952 650_7 $$2Other$$amultiple system atrophy
000163952 650_2 $$2MeSH$$aBrain: pathology
000163952 650_2 $$2MeSH$$aConsensus
000163952 650_2 $$2MeSH$$aHumans
000163952 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000163952 650_2 $$2MeSH$$aMultiple System Atrophy: diagnosis
000163952 650_2 $$2MeSH$$aMultiple System Atrophy: pathology
000163952 650_2 $$2MeSH$$aProspective Studies
000163952 7001_ $$00000-0003-1484-4717$$aStankovic, Iva$$b1
000163952 7001_ $$00000-0002-9051-7091$$aVignatelli, Luca$$b2
000163952 7001_ $$00000-0002-2854-4179$$aFanciulli, Alessandra$$b3
000163952 7001_ $$aCalandra-Buonaura, Giovanna$$b4
000163952 7001_ $$00000-0001-6503-1455$$aSeppi, Klaus$$b5
000163952 7001_ $$00000-0002-1345-6774$$aPalma, Jose-Alberto$$b6
000163952 7001_ $$00000-0003-2172-7527$$aMeissner, Wassilios G$$b7
000163952 7001_ $$00000-0002-4493-5073$$aKrismer, Florian$$b8
000163952 7001_ $$0P:(DE-2719)2000059$$aBerg, Daniela$$b9$$udzne
000163952 7001_ $$00000-0002-3633-8818$$aCortelli, Pietro$$b10
000163952 7001_ $$aFreeman, Roy$$b11
000163952 7001_ $$00000-0003-0422-8398$$aHalliday, Glenda$$b12
000163952 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b13$$udzne
000163952 7001_ $$aLang, Anthony$$b14
000163952 7001_ $$00000-0003-1532-3526$$aLing, Helen$$b15
000163952 7001_ $$aLitvan, Irene$$b16
000163952 7001_ $$aLow, Phillip$$b17
000163952 7001_ $$aMiki, Yasuo$$b18
000163952 7001_ $$aPanicker, Jalesh$$b19
000163952 7001_ $$aPellecchia, Maria Teresa$$b20
000163952 7001_ $$aQuinn, Niall$$b21
000163952 7001_ $$00000-0002-5803-169X$$aSakakibara, Ryuji$$b22
000163952 7001_ $$00000-0003-1668-9925$$aStamelou, Maria$$b23
000163952 7001_ $$aTolosa, Eduardo$$b24
000163952 7001_ $$aTsuji, Shoji$$b25
000163952 7001_ $$aWarner, Tom$$b26
000163952 7001_ $$aPoewe, Werner$$b27
000163952 7001_ $$00000-0002-1851-9981$$aKaufmann, Horacio$$b28
000163952 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.29005$$gp. mds.29005$$n6$$p1131-1148$$tMovement disorders$$v37$$x0885-3185$$y2022
000163952 8564_ $$uhttps://pub.dzne.de/record/163952/files/DZNE-2022-00626.pdf$$yOpenAccess
000163952 8564_ $$uhttps://pub.dzne.de/record/163952/files/DZNE-2022-00626.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163952 909CO $$ooai:pub.dzne.de:163952$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000163952 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2000059$$aExternal Institute$$b9$$kExtern
000163952 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000163952 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000163952 9141_ $$y2022
000163952 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000163952 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000163952 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-11
000163952 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000163952 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-11
000163952 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2021$$d2022-11-11
000163952 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-30$$wger
000163952 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000163952 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163952 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000163952 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-11
000163952 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2021$$d2022-11-11
000163952 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000163952 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000163952 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-11$$wger
000163952 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000163952 9201_ $$0I:(DE-2719)1111015$$kAG Höglinger 2$$lCoordinator of Clinical Parkinson Research$$x0
000163952 980__ $$ajournal
000163952 980__ $$aVDB
000163952 980__ $$aUNRESTRICTED
000163952 980__ $$aI:(DE-2719)1111015
000163952 9801_ $$aFullTexts